Yuankai Shi

机构：Chinese Academy of Medical Sciences & Peking Union Medical College

发表论文 56 篇 · 总被引 1631 次 · h-index 15

代表论文

• End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA (2021 · Blood Advances · 被引 57)
• Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study (2021 · Haematologica · 被引 56)
• Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors (2019 · Journal of Hematology & Oncology · 被引 36)
• Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma (2021 · Chinese Journal of Cancer Research · 被引 26)
• First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer (2020 · Journal of Hematology & Oncology · 被引 26)
• A pivotal phase 2 single-arm study of glecirasib (JAB-21822) in patients with NSCLC harboring KRAS G12C mutation. (2024 · Journal of Clinical Oncology · 被引 20)